KR20210066831A - 공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법 - Google Patents
공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20210066831A KR20210066831A KR1020217010564A KR20217010564A KR20210066831A KR 20210066831 A KR20210066831 A KR 20210066831A KR 1020217010564 A KR1020217010564 A KR 1020217010564A KR 20217010564 A KR20217010564 A KR 20217010564A KR 20210066831 A KR20210066831 A KR 20210066831A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- less
- baseline
- composition
- decrease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 238000003915 air pollution Methods 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 35
- 230000006806 disease prevention Effects 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 claims abstract description 32
- 230000004054 inflammatory process Effects 0.000 claims abstract description 32
- 239000013618 particulate matter Substances 0.000 claims abstract description 23
- 230000008719 thickening Effects 0.000 claims abstract description 23
- 210000001367 artery Anatomy 0.000 claims abstract description 22
- 230000036542 oxidative stress Effects 0.000 claims abstract description 21
- 206010048554 Endothelial dysfunction Diseases 0.000 claims abstract description 20
- 230000008694 endothelial dysfunction Effects 0.000 claims abstract description 20
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 76
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 62
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 60
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 59
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 49
- 230000009467 reduction Effects 0.000 claims description 47
- 230000007423 decrease Effects 0.000 claims description 43
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 32
- 239000000090 biomarker Substances 0.000 claims description 25
- 210000002216 heart Anatomy 0.000 claims description 25
- 150000002632 lipids Chemical group 0.000 claims description 23
- 108010069201 VLDL Cholesterol Proteins 0.000 claims description 17
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 16
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 16
- 239000011236 particulate material Substances 0.000 claims description 15
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 14
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 13
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 206010022489 Insulin Resistance Diseases 0.000 claims description 12
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 12
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 12
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 102000004895 Lipoproteins Human genes 0.000 claims description 11
- 108090001030 Lipoproteins Proteins 0.000 claims description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 9
- 230000007774 longterm Effects 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 8
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 8
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 8
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 7
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 7
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 7
- 229940118019 malondialdehyde Drugs 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 230000013632 homeostatic process Effects 0.000 claims description 6
- 230000003859 lipid peroxidation Effects 0.000 claims description 6
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims description 6
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 6
- 230000001590 oxidative effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 5
- 102000015439 Phospholipases Human genes 0.000 claims description 5
- 108010064785 Phospholipases Proteins 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 5
- 239000006014 omega-3 oil Substances 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000008859 change Effects 0.000 description 146
- 239000000902 placebo Substances 0.000 description 118
- 229940068196 placebo Drugs 0.000 description 118
- 230000004075 alteration Effects 0.000 description 66
- 229960002600 icosapent ethyl Drugs 0.000 description 51
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 48
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 47
- 210000002966 serum Anatomy 0.000 description 32
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 26
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 22
- 239000002775 capsule Substances 0.000 description 22
- 150000003626 triacylglycerols Chemical class 0.000 description 20
- 108010007622 LDL Lipoproteins Proteins 0.000 description 19
- 102000007330 LDL Lipoproteins Human genes 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 229940090949 docosahexaenoic acid Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 208000029078 coronary artery disease Diseases 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 229940114079 arachidonic acid Drugs 0.000 description 11
- 235000021342 arachidonic acid Nutrition 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 7
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 7
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 7
- 229960001295 tocopherol Drugs 0.000 description 7
- 239000011732 tocopherol Substances 0.000 description 7
- 235000010384 tocopherol Nutrition 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- -1 but not limited to Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 235000021068 Western diet Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 4
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 108010033266 Lipoprotein(a) Proteins 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 4
- SNXPWYFWAZVIAU-GKFVBPDJSA-N ethyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SNXPWYFWAZVIAU-GKFVBPDJSA-N 0.000 description 4
- GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229960000672 rosuvastatin Drugs 0.000 description 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- 208000014882 Carotid artery disease Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102000007513 Hemoglobin A Human genes 0.000 description 2
- 108010085682 Hemoglobin A Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DVSZKTAMJJTWFG-CPIIABRBSA-N (2z)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=C\C=C/C(O)=O DVSZKTAMJJTWFG-CPIIABRBSA-N 0.000 description 1
- MNVDOLYULIAMDA-AGRJPVHOSA-N (9z,12z,15z)-2-ethyloctadeca-9,12,15-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCC(CC)C(O)=O MNVDOLYULIAMDA-AGRJPVHOSA-N 0.000 description 1
- 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000006447 Phospholipases A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010060753 Type IV hyperlipidaemia Diseases 0.000 description 1
- QWDCYFDDFPWISL-UHFFFAOYSA-N UNPD207407 Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OC QWDCYFDDFPWISL-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QWDCYFDDFPWISL-JEBPEJKESA-N cis-5,8,11,14,17-eicosapentaenoic acid methyl ester Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC QWDCYFDDFPWISL-JEBPEJKESA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010021337 lipoprotein triglyceride Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000007406 plaque accumulation Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000008742 procoagulation Effects 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (46)
- 대상체에서 미립자 물질의 흡입에 의해 유도된 산화 스트레스, 내피 기능이상, 동맥의 좁아짐 및/또는 비후화, 및/또는 염증을 치료하거나 예방하는 방법으로서, 매일 약 4 g의 에이코사펜타엔산을 포함하는 조성물을 대상체에게 투여하는 단계를 포함하는, 방법.
- 제1항에 있어서, 미립자 물질은 약 10 μm 미만 및 약 2.5 μm 초과의 직경인, 방법.
- 제1항 또는 제2항에 있어서, 미립자 물질은 약 2.5 μm 이하의 직경인, 방법.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 미립자 물질은 약 0.1 μm 미만의 직경인, 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 염증은 폐 및/또는 전신 염증인, 방법.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물의 투여는 대상체에서의 죽상동맥경화성 심혈관 질환의 위험을 감소시키는, 방법.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 대상체는 혈압 수준의 감소를 경험하는, 방법.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 대상체는 인슐린 저항성의 감소를 경험하는, 방법.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 대상체는 혈관 내피 성장 인자(VEGF: vascular endothelial growth factor), 종양 괴사 인자-α(TNF-α: tumor necrosis factor-α), 단핵구 화학유인물질 단백질-1(MCP-1: monocyte chemoattractant protein-1), 인터류킨-1β(IL-1β: interleukin-1β), 가용성 세포내 부착 분자-1(sICAM-1: soluble intercellular adhesion molecule-1), 가용성 혈관 세포 부착 분자-1(sVCAM-1: soluble vascular cellular adhesion molecule-1), 고감도 반응성 단백질(hsCRP: high sensitivity reactive protein), 지단백 연관된 포스포리파제 A2(Lp-PLA2: lipoprotein-associated phospholipase A2) 및 순환 단핵구 수준으로 이루어진 군으로부터 선택되는 염증성 바이오마커의 감소를 경험하는, 방법.
- 제1항 내지 제9항 중 어느 한 항에 있어서, 대상체는 총 콜레스테롤(TC: total cholesterol), 초저밀도 지단백 콜레스테롤(VLDL-C: very low dense lipoprotein cholesterol), 저밀도 지단백 콜레스테롤(LDL-C: low dense lipoprotein cholesterol), 고밀도 지단백 콜레스테롤 (HDL-C: high dense lipoprotein cholesterol), 비고밀도 지단백 콜레스테롤(비-HDL-C: non-high dense lipoprotein cholesterol), HDL-C 기능성, 아포지단백 B(Apo B: apolipoprotein B), 인터류킨-6(IL-6: interleukin-6), 아포지단백 A-1(Apo A-1: apolipoprotein A-1) 및 인슐린 저항성의 항상성 모델 평가(HOMA-IR: homeostasis model assessment of insulin resistance) 수준으로 이루어진 군으로부터 선택되는 대사 바이오마커의 감소를 경험하는, 방법.
- 제1항 내지 제10항 중 어느 한 항에 있어서, 대상체는 지질 산화, 지질 과산화, 지질 하이드로과산화, 말론디알데하이드, 프로스타글란딘-2α(PGF-2α), 혈소판 유래된 성장 인자(PDGF: platelet-derived growth factor) 및 항산화제 가능성 수준으로 이루어진 군으로부터 선택되는 산화 바이오마커의 감소를 경험하는, 방법.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 대상체는 조성물의 투여 후 심박수 및/또는 심박동의 유리한 효과를 나타내는, 방법.
- 제12항에 있어서, 유리한 효과는 부정맥 억제 수준, 심실 부정맥 속도, 또는 심박수의 감소 또는 심박 변이도의 증가를 포함하는, 방법.
- 제1항 내지 제13항 중 어느 한 항에 있어서, 상기 조성물은 하루에 1개 내지 4개의 투여량 단위로 상기 대상체에게 투여되는, 방법.
- 제1항 내지 제14항 중 어느 한 항에 있어서, 에이코사펜타엔산 에틸 에스테르는 상기 조성물에서 적어도 약 96 중량%의 총 오메가-3 지방산을 포함하는, 방법.
- 대상체에서 공기 오염에 대한 장기간 노출 및/또는 단기간 노출에 의해 유도된 산화 스트레스, 내피 기능이상, 동맥의 좁아짐 및/또는 비후화, 및/또는 염증을 치료하거나 예방하는 방법으로서, 매일 약 4 g의 에이코사펜타엔산을 포함하는 조성물을 대상체에게 투여하는 단계를 포함하는, 방법.
- 제16항에 있어서, 공기 오염은 미립자 물질을 함유하는, 방법.
- 제16항 또는 제17항에 있어서, 미립자 물질은 약 10 μm 미만 및 약 2.5 μm 초과의 직경인, 방법.
- 제16항 내지 제18항 중 어느 한 항에 있어서, 미립자 물질은 약 2.5 μm 이하의 직경인, 방법.
- 제16항 내지 제19항 중 어느 한 항에 있어서, 미립자 물질은 약 0.1 μm 미만의 직경인, 방법.
- 제16항 내지 제20항 중 어느 한 항에 있어서, 염증은 폐 및/또는 전신 염증인, 방법.
- 제16항 내지 제21항 중 어느 한 항에 있어서, 상기 조성물의 투여는 대상체에서의 죽상동맥경화성 심혈관 질환의 위험을 감소시키는, 방법.
- 제16항 내지 제22항 중 어느 한 항에 있어서, 대상체는 혈압 수준의 감소를 경험하는, 방법.
- 제16항 내지 제23항 중 어느 한 항에 있어서, 대상체는 인슐린 저항성의 감소를 경험하는, 방법.
- 제16항 내지 제24항 중 어느 한 항에 있어서, 대상체는 혈관 내피 성장 인자(VEGF), 종양 괴사 인자-α(TNF-α), 단핵구 화학유인물질 단백질-1(MCP-1), 인터류킨-1β(IL-1β), 가용성 세포내 부착 분자-1(sICAM-1), 가용성 혈관 세포 부착 분자-1(sVCAM-1), 고감도 반응성 단백질(hsCRP), 지단백 연관된 포스포리파제 A2(Lp-PLA2) 및 순환 단핵구 수준으로 이루어진 군으로부터 선택되는 염증성 바이오마커의 감소를 경험하는, 방법.
- 제16항 내지 제25항 중 어느 한 항에 있어서, 대상체는 총 콜레스테롤(TC), 초저밀도 지단백 콜레스테롤(VLDL-C), 저밀도 지단백 콜레스테롤(LDL-C), 고밀도 지단백 콜레스테롤 (HDL-C), 비고밀도 지단백 콜레스테롤(비-HDL-C), HDL-C 기능성, 아포지단백 B(Apo B), 인터류킨-6(IL-6), 아포지단백 A-1(Apo A-1) 및 인슐린 저항성의 항상성 모델 평가(HOMA-IR) 수준으로 이루어진 군으로부터 선택되는 대사 바이오마커의 감소를 경험하는, 방법.
- 제16항 내지 제26항 중 어느 한 항에 있어서, 대상체는 지질 산화, 지질 과산화, 지질 하이드로과산화, 말론디알데하이드, 프로스타글란딘-2α(PGF-2α), 혈소판 유래된 성장 인자(PDGF) 및 항산화제 가능성 수준으로 이루어진 군으로부터 선택되는 산화 바이오마커의 감소를 경험하는, 방법.
- 제16항 내지 제27항 중 어느 한 항에 있어서, 대상체는 조성물의 투여 후 심박수 및/또는 심박동의 유리한 효과를 나타내는, 방법.
- 제28항에 있어서, 유리한 효과는 부정맥 억제 수준, 심실 부정맥 속도, 또는 심박수의 감소 또는 심박 변이도의 증가를 포함하는, 방법.
- 제16항 내지 제29항 중 어느 한 항에 있어서, 상기 조성물은 하루에 1개 내지 4개의 투여량 단위로 상기 대상체에게 투여되는, 방법.
- 제16항 내지 제30항 중 어느 한 항에 있어서, 에이코사펜타엔산 에틸 에스테르는 상기 조성물에서 적어도 약 96 중량%의 총 오메가-3 지방산을 포함하는, 방법.
- 대상체에서 미립자 물질의 흡입에 의해 유도된 산화 스트레스, 내피 기능이상, 동맥의 좁아짐 및/또는 비후화, 및/또는 염증을 치료하거나 예방하는 방법으로서, 매일 약 4 g의 에이코사펜타엔산을 포함하는 조성물을 대상체에게 투여하는 단계를 포함하고, 상기 조성물의 투여는 대상체에서 죽상동맥경화성 심혈관 질환의 위험을 감소시키는, 방법.
- 제32항에 있어서, 공기 오염은 미립자 물질을 함유하는, 방법.
- 제32항 또는 제33항에 있어서, 미립자 물질은 약 10 μm 미만 및 약 2.5 μm 초과의 직경인, 방법.
- 제32항 내지 제34항 중 어느 한 항에 있어서, 미립자 물질은 약 2.5 μm 이하의 직경인, 방법.
- 제32항 내지 제35항 중 어느 한 항에 있어서, 미립자 물질은 약 0.1 μm 미만의 직경인, 방법.
- 제32항 내지 제36항 중 어느 한 항에 있어서, 염증은 폐 및/또는 전신 염증인, 방법.
- 제32항 내지 제37항 중 어느 한 항에 있어서, 대상체는 혈압 수준의 감소를 경험하는, 방법.
- 제32항 내지 제38항 중 어느 한 항에 있어서, 대상체는 인슐린 저항성의 감소를 경험하는, 방법.
- 제32항 내지 제39항 중 어느 한 항에 있어서, 대상체는 혈관 내피 성장 인자(VEGF), 종양 괴사 인자-α(TNF-α), 단핵구 화학유인물질 단백질-1(MCP-1), 인터류킨-1β(IL-1β), 가용성 세포내 부착 분자-1(sICAM-1), 가용성 혈관 세포 부착 분자-1(sVCAM-1), 고감도 반응성 단백질(hsCRP), 지단백 연관된 포스포리파제 A2(Lp-PLA2) 및 순환 단핵구 수준으로 이루어진 군으로부터 선택되는 염증성 바이오마커의 감소를 경험하는, 방법.
- 제32항 내지 제40항 중 어느 한 항에 있어서, 대상체는 총 콜레스테롤(TC), 초저밀도 지단백 콜레스테롤(VLDL-C), 저밀도 지단백 콜레스테롤(LDL-C), 고밀도 지단백 콜레스테롤 (HDL-C), 비고밀도 지단백 콜레스테롤(비-HDL-C), HDL-C 기능성, 아포지단백 B(Apo B), 인터류킨-6(IL-6), 아포지단백 A-1(Apo A-1) 및 인슐린 저항성의 항상성 모델 평가(HOMA-IR) 수준으로 이루어진 군으로부터 선택되는 대사 바이오마커의 감소를 경험하는, 방법.
- 제32항 내지 제41항 중 어느 한 항에 있어서, 대상체는 지질 산화, 지질 과산화, 지질 하이드로과산화, 말론디알데하이드, 프로스타글란딘-2α(PGF-2α), 혈소판 유래된 성장 인자(PDGF) 및 항산화제 가능성 수준으로 이루어진 군으로부터 선택되는 산화 바이오마커의 감소를 경험하는, 방법.
- 제32항 내지 제42항 중 어느 한 항에 있어서, 대상체는 상기 조성물의 투여 후 심박수 및/또는 심박동의 유리한 효과를 나타내는, 방법.
- 제43항에 있어서, 유리한 효과는 부정맥 억제 수준, 심실 부정맥 속도, 또는 심박수의 감소 또는 심박 변이도의 증가를 포함하는, 방법.
- 제32항 내지 제44항 중 어느 한 항에 있어서, 상기 조성물은 하루에 1개 내지 4개의 투여량 단위로 상기 대상체에게 투여되는, 방법.
- 제32항 내지 제45항 중 어느 한 항에 있어서, 에이코사펜타엔산 에틸 에스테르는 상기 조성물에서 적어도 약 96 중량%의 총 오메가-3 지방산을 포함하는, 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862736897P | 2018-09-26 | 2018-09-26 | |
US62/736,897 | 2018-09-26 | ||
PCT/IB2019/001059 WO2020065402A1 (en) | 2018-09-26 | 2019-09-25 | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210066831A true KR20210066831A (ko) | 2021-06-07 |
Family
ID=68387354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217010564A Ceased KR20210066831A (ko) | 2018-09-26 | 2019-09-25 | 공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210330624A1 (ko) |
EP (1) | EP3856171A1 (ko) |
JP (1) | JP2022502401A (ko) |
KR (1) | KR20210066831A (ko) |
CN (1) | CN113164426A (ko) |
AU (1) | AU2019346108A1 (ko) |
BR (1) | BR112021005813A2 (ko) |
CA (1) | CA3113177A1 (ko) |
MX (1) | MX2021003264A (ko) |
PH (1) | PH12021550698A1 (ko) |
TW (1) | TW202027737A (ko) |
WO (1) | WO2020065402A1 (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
RU2538691C2 (ru) | 2009-04-29 | 2015-01-10 | Амарин Фарма, Инк. | Стабильные фармацевтические композиции и способы их применения |
CN102625847A (zh) | 2009-06-15 | 2012-08-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
HUE053111T2 (hu) | 2012-06-29 | 2021-06-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
EP4326244A4 (en) | 2021-04-21 | 2025-03-19 | Amarin Pharmaceuticals Ie Ltd | METHODS FOR REDUCING THE RISK OF HEART FAILURE |
CA3217098A1 (en) * | 2021-04-29 | 2022-11-03 | Richard Louis Dunbar | Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject |
CN113384568B (zh) * | 2021-06-04 | 2022-11-15 | 广东工业大学 | 预防和/或修复大气污染导致的心脏损伤的联合用药物 |
FR3151183A1 (fr) * | 2023-07-20 | 2025-01-24 | Microphyt | Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10172818B2 (en) * | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2016095778A1 (zh) * | 2014-12-15 | 2016-06-23 | 帝斯曼知识产权资产管理有限公司 | 治疗或预防与空气污染有关的疾病的方法 |
-
2019
- 2019-09-25 BR BR112021005813-3A patent/BR112021005813A2/pt not_active Application Discontinuation
- 2019-09-25 CA CA3113177A patent/CA3113177A1/en active Pending
- 2019-09-25 JP JP2021516886A patent/JP2022502401A/ja active Pending
- 2019-09-25 TW TW108134626A patent/TW202027737A/zh unknown
- 2019-09-25 EP EP19795317.7A patent/EP3856171A1/en not_active Withdrawn
- 2019-09-25 WO PCT/IB2019/001059 patent/WO2020065402A1/en not_active Application Discontinuation
- 2019-09-25 KR KR1020217010564A patent/KR20210066831A/ko not_active Ceased
- 2019-09-25 CN CN201980077903.0A patent/CN113164426A/zh active Pending
- 2019-09-25 MX MX2021003264A patent/MX2021003264A/es unknown
- 2019-09-25 AU AU2019346108A patent/AU2019346108A1/en not_active Abandoned
- 2019-09-25 US US17/280,092 patent/US20210330624A1/en not_active Abandoned
-
2021
- 2021-03-26 PH PH12021550698A patent/PH12021550698A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12021550698A1 (en) | 2021-11-22 |
US20210330624A1 (en) | 2021-10-28 |
BR112021005813A2 (pt) | 2021-06-29 |
WO2020065402A1 (en) | 2020-04-02 |
JP2022502401A (ja) | 2022-01-11 |
CN113164426A (zh) | 2021-07-23 |
AU2019346108A1 (en) | 2021-04-29 |
MX2021003264A (es) | 2021-05-12 |
CA3113177A1 (en) | 2020-04-02 |
TW202027737A (zh) | 2020-08-01 |
EP3856171A1 (en) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20210066831A (ko) | 공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법 | |
US20230310372A1 (en) | Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof | |
US11285127B2 (en) | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | |
US20210069145A1 (en) | Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof | |
US10206898B2 (en) | Compositions and methods for treating or preventing obesity in a subject in need thereof | |
AU2016269422B2 (en) | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same | |
US10561631B2 (en) | Methods of reducing RLP-C | |
KR101958515B1 (ko) | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 | |
US20150073050A1 (en) | Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof | |
US20150250757A1 (en) | Methods for treating hypertriglyceridemia | |
HK40056640A (en) | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution | |
HK40068490A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
HK1173749A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20210409 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220921 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20241130 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20250207 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |